[Mechanisms of formation of chronic low back pain relapse and their correction in patients with dorsopathy].
A clinical-neurological, psychological, biochemical and electromyographic study of 40 operated and 40 non-operated patients with chronic low back pain syndrome was conducted before and after treatment. The authors used various modes of administration of xydifonum, a chelate from the group of bisphosphonates, including electrophoretic, peroral and administration in the form of ointment, administered in turn with heparin one to improve the antiplatelet effect, using photopheresis the with the help of the state-of-the art photomatrix LED equipment. The application of Ca2+-modulating properties of xydifonum demonstrate its universality in achieving of analgesic, muscle-relaxing, anxiolytic and antidepressant effects thus allowing to exclude polypragmasy. This is a main difference between this drug and other medications with limited effects. Based on the results obtained, the authors propose a scheme of development of chronic low back pain.
Seleznev
A N
AN
Sabilo
E S
ES
Savin
A A
AA
Riabov
A G
AG
Kozlov
S A
SA
Zima
L N
LN
Zmievskoĭ
G N
GN
D000465:Algorithms; D001007:Anxiety / Q000175:diagnosis / Q000523:psychology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003863:Depression / Q000175:diagnosis / Q000523:psychology; D018450:Disease Progression; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures / Q000706:statistics & numerical data; D012008:Recurrence; D012720:Severity of Illness Index
D050071:Bone Density Conservation Agents; D012968:Etidronic Acid